NYLI Candriam International Equity ETF (IQSI) is an exchange-traded fund that seeks investment results tracking the NYLI Candriam International Equity Index, before fees and expenses, providing passive exposure to foreign developed market large- and medium-cap equity securities of companies satisfying environmental, social, and governance (ESG) criteria developed by Candriam. The fund offers a low-cost (0.15% net expense ratio after waivers), tax-efficient structure for diversified international equity exposure across sectors including financials (21.90%), industrials (16.20%), information technology (13.12%), and health care (12.79%); key holdings include ASML Holding NV (3.01%), SAP SE (2.19%), Roche Holding AG (1.91%), Novartis AG (1.91%), and Nestle S.A. (1.89%). It operates across 23 countries and 13 currencies, with primary geographic allocations to Japan (26.76%), the United Kingdom (11.84%), Switzerland (10.38%), Australia (9.24%), and Germany (8.48%), targeting investors seeking ESG-integrated core equity holdings for income and capital appreciation potential in developed markets outside North America.
Launched on December 17, 2019, and listed on NYSE Arca, the ETF is managed by New York Life Investment Management LLC, with Candriam—a wholly owned subsidiary of New York Life Investment Management Holdings LLC—serving as index consultant leveraging its industry-leading ESG research.
In August 2024, the fund underwent a significant rebranding from IQ Candriam International Equity ETF to NYLI Candriam International Equity ETF, reflecting closer alignment with New York Life Investments branding; as of September 30, 2025, it holds total net assets of $220.29 million across 580 holdings, with a Morningstar Medalist Rating and weighted average market cap of $95.11 billion.